Abstract
Whilst it is now widely recognised that routine immunisation (RI) was disrupted by the COVID-19 pandemic in 2020 compared to previous immunisation performance, the extent of continued interruptions in 2021 and/or rebounds to previous trends remains unclear, with sporadic surveys reporting signs of immunisation system recovery at the end of 2020.
We modelled country-specific RI trends using validated estimates of national coverage from the World Health Organisation and United Nation Children’s Fund for over 160 countries, to project expected diphtheria, tetanus, and pertussis-containing vaccine first-dose (DTP1), third-dose (DTP3) and measles-containing vaccine first-dose (MCV1) coverage for 2021 based on pre-pandemic trends (from 2000-2019).
We estimated a 3·6% (95%CI: [2·6%; 4·6%]) decline in global DTP3 coverage in 2021 compared to 2000-2019 trends, from an expected 90·1% to a reported 86·5% across 164 reporting countries, and similar results for DTP1 (2·8% decline; 95%CI: [2·0%; 3·6%]), and for MCV1 (3·8% decline; 95%CI: [4·8%; 2·7%]). 86·5% global coverage in 2021 represents a further decrease from that reported in 2020 and 2019, and translates to a 16-year setback in RI coverage, i.e., 2005 levels. Hypothesised and early signals of rebounds to pre-pandemic coverage were not seen in most countries. The Americas, Africa, and Asia were the most impacted regions, with low- and middle-income countries the most affected income groups.
The number of Zero Dose children also continued to increase in 2021. DTP1 coverage declined worldwide from an expected 93·7% to a reported 90·9% (2·8% decline; 95%CI: [2·0%; 3·6%]) which translates into an additional 3.4 million Zero Dose children on top of an expected 11.0 million (30.9% increase) at the global level.
We hope this work will provide an objective baseline to inform future interventions and prioritisation aiming to facilitate rebounds in coverage to previous levels and catch-up of growing populations of under- and un-immunised children.
Competing Interest Statement
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: It is noted that BE has been employed by the Clinton Health Access Initiative in the Global Vaccines team in the last three years; and is currently employed by Gavi. All research contained in this manuscript was conducted during a doctorate qualification, outside and independent of employment. Neither facilities, data, nor any other forms of input from the Clinton Health Access Initiative or Gavi, were used in this study. The research and manuscript are independent of the Clinton Health Access Initiative and Gavi, and the findings have not been discussed, reviewed, or endorsed by the Clinton Health Access Initiative, the Gavi Secretariat, or any Alliance members.
Funding Statement
TJ acknowledges funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union. OK was funded by the Swiss National Science Foundation (grant number PP00P3_202660). These funders had no role in the design and conduct of this study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. BE is a PhD student at the Institute of Global Health, Faculty of Medicine, University of Geneva and received no funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced are available online on GitHub - https://github.com/bevans249/modelling_covid_impact_RI
